ImmunNovative Developments
Contact details
Carrer Baldiri Reixac, 4-8 Torre R, Oficina 2B9
08028 Barcelona (Barcelona)
Espanya
Telephone: +34 934 031 945
jlfalco@immunnovative.com
Visit Website
Contact person
Francisco Lozano Soto, Principal Investigator | jlfalco@immunnovative.com
General information
Type of organization: Company
Founding year: 2010
Origin of the group: University
Number of locations worldwide: 1
Number of locations in Catalonia: 1
Business model and activity description
Description
ImmunNovative Developments S.L. is a biomed spin-off company founded in February 2010, based on product development for the prevention, diagnosis and treatment of sepsis and other inflammatory immune-based diseases
Main activities
- >> Innovation
- >> Manufacturing
- >> R&D
Main areas
- >> Biotechnology
- >> Human Health: Pharmacological or Biological Therapeutics
R&D lines
Our pipeline is based i 4 terapeutic areas:1) Sepsis: rshCD5 (fungal sepsis) and rshCD6 (bacterial sepsis)2) Oncology: Human anti-human mAbs3) Auto-immunity: Human anti-human mAbs4) I/R damage: Cross-species blocking mAbs
Therapeutic areas
- >> Cardiovascular
- >> Central Nervous System
- >> Infectious diseases
- >> Inflammatory diseases
- >> Immunology
- >> Oncology
Technologies
- >> Bioinformatics
- >> Biostatistics
- >> In silico analysis
- >> Peptides & proteins
- >> Omics
Differential features of the technology used, main facilities and/or instrumentations available
Our rshCD5 and rshCD6 drugs have many competitive advantages:1) First in class technology2) Broad spectrum of action3) No generation of bacterial/fungal resistance4) Absence of toxicity and immunogenicity
Results and development
Services and products
CD5 and CD6 are SRCR proteins (Scavenger Receptor Cysteine-rich domain) as part of our lymphocyte cell membrane. Its role is to recognize drug elements of the cell membrane of pathogens and trigger the immune response of our body against infection. CD5 is able to recognize all types of fungi (saprophytic and pathogenic), and CD6 is capable of recognizing bacterial G + and G- and is also able to recognize fungi. Recombinant proteins of CD5 and CD6 may be used in the treatment of sepsis.
Alliances and development opportunities
Our business model goes through a exclusive license agreement with a pharmaceutical company, having completed proof of concept in humans in clinical phase I / IIa.
Last updated
04/05/2012